Daraxonrasib is the first approved RAS-targeted therapy in pancreatic cancer Approval based primarily on Dana-Farber-led RASolute 302 trial showing daraxonrasib nearly doubled med ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results